natgillin/translations-raw huggingface dataset:
Mice of a control group were injected the 0.9% solution of NaCl or 5% dextrose solution in the volume of 0.8 ml. In a day after being infected, during 3 days, the tested mice were daily intravenously injected with the indicated above antimicrobial preparations, dissolved in 0.9% solution of NaCl or in 5% dextrose solution, as well as their solutions prepared based on the pharmaceutical composition (as described hereinabove). 
miješanje antimikrobne otopine s praškastom smjesom intenzivnom trešnjom, kako bi se dobila antimikrobna otopina za infuziju; i - razrjeđivanje pripremljene antimikrobne infuzijske otopine bilo u 50-200 ml 0,45 %-tne ili 0,9 % -tne otopine natrijevog klorida, ili u 50-200 ml 2 %-tne ili 5 %-tne otopine dekstroze, u skladu s praškastom smjesom koja sadrži natrijev klorid u prahu ili dekstrozu u prahu, kako bi se dobio pripravak antimikrobne otopine za infuziju spreman za uporabu.
The antibody, immunoconjugate, bispecific or multispecific molecule, pharmaceutical composition or expression vector for use according to claim 22, wherein the one or more further therapeutic agents are selected from a group consisting of cisplatin, gefitinib, cetuximab, rituximab, bevacizumab, erlotinib, bortezomib, thalidomide, pamidronate, zoledronic acid, clodronate, risendronate, ibandronate, etidronate, alendronate, tiludronate, arsenic trioxide, lenalidomide, filgrastim, pegfilgrastim, sargramostim, suberoylanilide hydroxamic acid, and SCIO-469. 
Protutijelo, imunokonjugat, farmaceutski pripravak, bispecifična ili multispecifična molekula za uporabu u skladu s patentnim zahtjevom 22, naznačena time što je jedno ili više daljnjih terapijskih sredstava odabrano iz skupino koja se sastoji od cisplatina, gefitiniba, cetuksimaba, rituksimaba, bevacizumaba, erlotiniba, bortezomiba, talidomida, pamidronata, zoledronske kiseline, klodronata, porandronata, ibandronata, etidronata, alendronata, tiludronata, arsenovog trioksida, lenalidomida, filgrastima, pegfilgrastima, sargramostima, suberoilanilid- hidroksamične kiseline i SCIO-469.
The device of claim 13, further comprising: an interface to the user localization system. 
međusklop prema sustavu za lokalizaciju korisnika za prijem karte gustoće korisnika.
SEQ ID NOs: 63 and 66, respectively. 
SEK ID BR-a: 63 1 66, respektivno.
A compound, or a pharmaceutically acceptable salt thereof, for use according to claim 5, wherein administration is via a medicament dispenser selected from a reservoir dry powder inhaler, a multi-dose dry powder inhaler or a metered dose inhaler. 
Spoj, ili njegova farmaceutski prihvatljiva sol, namijenjen upotrebi u skladu s patentnim zahtjevom 5, naznačen time što se primjena provodi putem dozatora za medikament koji se bira između inhalatora sa spremnikom suhog praha, višedoznog inhalatora sa suhim prahom ili inhalatora za odmjerene doze.
The Poloxamer 188 and Polyvinylpyrrolidone K-30 were dissolved and mixed in a stainless steel container mixer with stirrer, the clarithromycin was suspended in this solution. 
Voda 400.0 g Poloxamer 188 i Polivinilpirolidon K-30 se otope i miješaju u spremniku od nehrđajućeg čelika mješalicom, klaritromicin se suspenzira u ovoj otopini.
The method of claim 1, wherein the refrigerant exhibits a boiling point below about -35°C. 
Postupak prema Zahtjevu 1, gdje rashladno sredstvo pokazuje točku vrenja ispod oko -35"C.
The nucleic acid of claim 1 or 2, wherein the anti-B7RP1 antibody is a human or humanized IgG2 antibody, or a human or humanized IgG4 antibody. 
Bispecifični protein prema patentnom zahtjevu 1 ili 2, naznačen time što je anti-B7RP1 antitijelo humano ili humanizirano IgG2 antitijelo, ili humano ili humanizirano IgG4 antitijelo.
at least one oxygen containing organic solvent. A pre-formulation comprising a low viscosity mixture of: 
najmanje jedno organsko otapalo koje sadrži kisik; i vodenu tekuću fazu;
A compound of formula (I) 
20 Spoj formulom (I)
Container (1) for storing and unloading bulk material comprising: a vessel (2) presenting a closed end (3) and an opened end (4), 
Spremnik (1) za skladištenje i istovar rasutog materijala koji sadrži posudu (2) sa zatvorenim (3) i otvorenim krajem (4), naznačen time što sadrži:
The compound or salt for use according to claim 16, wherein said myeloproliferative disorder is myeloid metaplasia with myelofibrosis (MMM). 
Spoj ili sol prema zahtjevu 69 naznačen time da navedeni mijeloproliferativni poremećaj (MPD) je mijeloidna metaplazija sa mijelofibrozom (MMM).
Upwardly oriented storage according to claim 1, wherein at least a part of a side wall (130, 131, 132) of the storage is movable for providing a modification of the shape of the interior space (110, 112), particularly for providing an increase of the cross section (11, 113) of the interior space in an area proximal to an opening provided for emptying the storage. 
Prema gore orijentirano skladište prema bilo kojem od prethodnih patentnih zahtjeva, naznačeno time, što je bar dio bočnog zida (130, 131, 132) skladišta pokretan da bi se omogućila promjena oblika unutrašnjosti (110, 112) skladišnog prostora, posebno za omogućavanje povećanja poprečnog presjeka (11, 113) unutrašnjosti skladišnog prostora u području koje se nalazi u blizini otvora predviđenog za pražnjenje skladišta.
Antibodies of the present invention may optionally be conjugated to a growth inhibitory agent or cytotoxic agent such as a toxin, including, for example, an auristatin, an antibiotic, a radioactive isotope, a nucleolytic enzyme, or the like. 
Imunokonjugat prema bilo kojem od zahtjeva 1 do 7, naznačen time, da je citotoksični agens odabran od sljedećih: toksin, kemoterapeutsko sredstvo, dio molekule lijeka, antibiotik, radioaktivni izotop, i nukleolitički enzim.
A process according to claim 5 or 6 for the manufacture of a salt of escitalopram characterised in that an impurity of the formula (II) wherein Z is cyano, R1 is methyl and R2 is hydrogen is removed from or reduced in the escitalopram by the process. 
Postupak prema zahtjevu 16 ili 17 za proizvodnju soli escitaloprama, naznačen time, što se nečistoća formule (II) [image] gdje je Z cijano, R1 je metil i R2 je vodik, postupkom uklanja ili smanjuje u escitalopramu.
Disclosed is a compound of Formula (Ia) wherein: 
Spoj formule (la) naznačen time da:
A compound represented by the following formula (I) or salt thereof. wherein R1 represents the formula -A11-A12; 
Spoj prikazan sa formulom (I) ili njegova sol: [image] naznačen time da predstavlja formulu -A11-A12;
Method according to claim 1, where a filter is made online and hereby opened for inflow and a filter is made offline and hereby closed for inflow by opening and closing, respectively, system valves upstream and downstream of the filter. 
– gdje se filtar uključi i tako otvori za dotok, a zatim se filtar isključi i tako zatvori za dotok otvaranjem odnosnom zatvaranjem sustavnih ventila uzvodno i nizvodno od filtra;
The method according to claim 1, wherein for the assembly between the semimanufactured component of the upper and the membrane, thermo-adhesive glue is distributed on the surface of said membrane in contact with the semimanufactured component of the upper so as to not compromise the vapor permeability of the assembly. 
Postupak u skladu s patentnim zahtjevom 1, naznačen time, da se radi dobivanja spoja između gornjišta (12) i membrane (13) termoadhezivno ljepilo nanosi se na površinu navedene membrane (13) koja je u kontaktu s gornjištem (12) kako se ne bi ugrozila njezina paropropusnost.
iii) constant heavy and light chains that are from a human antibody. The antibody of claim 1, wherein said antibody has one or more mutations in the Fc domain that modulate one or more effector functions. 
Molekula protutijela prema zahtjevu 1 ili 2, naznačena time, da navedena molekula protutijela ima jednu ili više mutacija u Fc-domeni, koje moduliraju jednu ili više djelotvornih funkcija, poželjno navedena modulacija djelotvorne funkcije je povećanje u citotoksičnosti posredstvom stanice koja je ovisna o protutijelu.
morphine), CB1 receptor agonists, bradykinin receptor antagonists, substance P antagonists. 
morfin), CB, receptor agonisti, bradikinin receptor antagonisti, tvari koje su P antagonisti.
The pumping rate of pump 40 can be calibrated for a range of application rates per ton harvested crop per hour. 
Kapacitet pumpanja pumpe 40 može se kalibrirati za jedan opseg količina nanošenja po toni ubranog usjeva na sat.
Container (1) for storing and unloading bulk material comprising a vessel (2) presenting a closed extremity (3) and an opened extremity (4), characterized in that it comprises: 
PATENTNI ZAHTJEVI L Spremnik (1) za skladištenje i istovar rasutog materijala koji sadrži posudu (2) sa zatvorenim (3) i otvorenim krajem (4), naznačen time što sadrži:
a heavy-chain variable region consisting of the amino acid sequence shown by SEQ ID NO:15 and a light-chain variable region consisting of the amino acid sequence shown by SEQ ID NO:9. 
varijabilno područje jakog lanca koje se sastoji od aminokiselinske sekvence prikazane sa SEQ ID NO:15 i varijabilno područje slabog lanca koje se sastoji od aminokiselinske sekvence prikazane sa SEQ ID NO:9;
The antibody molecule composition according to any one of claims 19 to 31, wherein said antibody molecule recognizes cancer, tumor or metastasis, or at least one cancer cell or tumor cell in at least one human. 
Pripravak s molekulom protutijela u skladu s bilo kojim od patentnih zahtjeva 19 do 31, naznačen time što navedena molekula protutijela prepoznaje rak, tumor ili metastazu, ili najmanje jednu stanicu raka ili tumorsku stanica kod najmanje jednog čovjeka.
The system (100) as claimed in claim 13, wherein the mobile application part message corresponds to one of location update, location update for general packet radio service, mobile originated /mobile terminated short message service, /mobile terminated voice calls and general packet radio service Session Flow. 
Sustav (100) temeljem zahtjeva 13, naznačen timešto poruka dijela mobilne aplikacije odgovara jednom ažuriranju lokacije, ažuriranju lokacije za GPRS, izvorno mobilnoj/mobilno završenoj SMS poruci, /mobilno završenim govornim pozivima i GPRS Tijeku razdoblja razmjene podataka.
A method of manufacture of a medicament for the treatment of fungal infections of the human or animal body characterised in the use of an antibody or an antigen binding fragment thereof specific for at least one epitope of hsp90 from an organism of the Aspergillus genus, and at least one antifungal agent selected from the group consisting of: itraconazole and voriconazole. 
Postupak za proizvodnju lijeka za liječenje gljivičnih infekcija ljudskog ili životinjskog tijela naznačen time što se koristi antitijelo ili njegov dio koji se vežu za antigene koji su specifični za najmanje jedan epitop hsp90 iz organizma roda Aspergillus, i najmanje jedno anti-gljivično sredstvo izabrano iz grupe koju čine: itrakonazol i vorikonazol.
and R5 are independently hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted cycloalkenyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted heterocycloalkenyl, substituted or unsubstituted aryl, substituted or unsubstituted fused ring aryl, or substituted or unsubstituted heteroaryl; and 
je vodik, halogen, supstituirani ili nesupstituirani alkil, supstituirani ili nesupstituirani heteroalkil, supstituirani ili nesupstituirani cikloalkil, supstituirani ili nesupstituirani cikloalkenil, supstituirani ili nesupstituirani heterocikloalkil, supstituirani ili nesupstituirani heterocikloalkenil, supstituirani ili nesupstituirani aril, supstituirani ili nesupstituirani kondenzirani arilni prsten, ili supstituirani ili nesupstituirani heteroaril; i
is selected from the group consisting of -NR3R4 and -OR3, wherein R3 and R4 are selected independently from the group consisting of H, substituted or non-substituted non-cyclic aliphatic group of C1 to C24 and substituted or non-substituted alicyclyl group of C1 to C24; 
je odabran iz skupine koju čine -NR3R4 i -OR3, pri čemu R3 i R4 su odabrani neovisno iz skupine koju čine H, supstituirana ili nesupstituirana neciklička alifatska skupina od C1 do C24 i supstituirana ili nesupstituirana aliciklička skupina od C1 do C24;
at least one hardened high molecular weight polyethylene oxide (PEO), wherein said high molecular weight PEO has an approximate molecular weight of from 4 million to 8 million, based upon rheological measurements, and is present in an amount of at least about 30% (by weight) of the core; 
Oralni farmaceutski oblik doziranja u krutom stanju sa produljenim otpuštanjem prema zahtjevu 1, naznačen time da pripravak sadrži najmanje oko 80 % (težinski) polietilen oksida koji ima, prema reološkim mjerenjima, približnu molekularnu težinu od najmanje 1,000,000.
The compound according to claim 1 wherein R8 is optionally substituted C0-C3alkylcarbocyclyl or optionally substituted C0-C3alkylheterocyclyl. 
Spoj u skladu sa zahtjevom 26 ili 27, naznačen time, da R8 je po izboru supstituiran C0-C3alkilkarbocikl ili po izboru supstituiran C0-C3alkilheterocikl.
dissolving rifaximin in diethylene glycol monoethyl ether (DEGME), in a DEGME: rifaximin molar ratio ranging from about 4:1 to about 500:1, at temperatures ranging from room temperature to 100°C, for a duration of time ranging from 5 minutes to 5 hours to obtain a rifaximin solution; 
– otapanja rifaksimina u dietilen-glikol-monoetil-eteru (DEGME), u molarnom omjeru DEGME:rifaksimin u rasponu od 4:1 do 500:1, na temperaturama u rasponu od sobne temperature do 100 °C, u trajanju u rasponu od 5 minuta do 5 sati kako bi se dobilo otopinu rifaksimina;
An anticancer agent comprising a compound according to any one of claims 1 to 9 or a salt thereof as an active ingredient. An anticancer agent according to claim 13, wherein the cancer is any selected from lung cancer, breast cancer, p=ostate cancer, colon cancer, acute myeloid leukemia, malignant lymphoma, retinoblastoma, neuroblastoma, and sarcoma. 
Protukancerogeni agens kao aktivni sastojak obuhvaća tvar u skladu s bilo kojim od patentnih zahtjeva 1 do 9 ili njenu sol. Protukancerogeni agens u skladu s patentnim zahtjevom 13, pri čemu je karcinom bilo koji odabran između karcinoma pluća, karcinoma dojke, karcinoma prostate, karcinoma kolona, akutne mijeloične leukemije, malignog limfoma, retinoblastoma, neuroblastoma i sarkoma. HR P20140409 T1
Ar is unsubstituted phenyl; or phenyl substituted with halo, trifluoromethyl, morpholinyl or hydroXyC1-3alkyl; or a pharmaceutically acceptable salt or a solvate thereof 
Ar je nesupstituirani fenil; ili fenil supstituiran s halo, trifluorometil, morfolinil ili hidroksiC; salkil; ili njegova farmaceutski prihvatljiva sol ili solvat.
with a compound having the formula 
Spoj naznačen time da ima formulu
LG is a suitable leaving group like a halide (Br, Cl, I). 
OS je pogodna odlazna skupina poput halida (Br, Cl, I).
The change in tension caused by the resulting contraction of the tissue is noted. 
Promjena u naponu koja je izazvana nastalom kontrakcijom se notira.
A composition comprising compound having a structure of Formula 8 or stereoisomer thereof or pharmaceutically acceptable salt thereof, wherein n and m are as recited in claim 1. 
Sastav sadrži tvar koja ima strukturu Formule 8 ili njen stereoizomer ili njenu farmaceutski prihvatljivu sol, pri čemu su n i m opisani u patentnom zahtjevu 1. [image]
In another embodiment, in formula (VII), X42 is CR44, and R43 and R44, taken together with the carbon atoms to which they are attached, form a cycloalkenyl, aryl, heterocyclyl, or heteroaryl ring. 
Spoj prema zahtjevu 19, pri čemu Xpje CR4y; Yao je CRg 1 R43 1 Ra zajedno sa ugljikovim atomima za koje su vezani čine cikloalkenil, aril, heterociklil ili heteroaril prsten.
wherein the DNA-targeting RNA is capable of forming a complex with the Cas9 protein and hybridization of the targeter-RNA to the target sequence is capable of targeting the Cas9 protein to the target DNA; and 
segment koji cilja na DNK, te koji obuhvaća nukleotidnu sekvencu koja je komplementarna ciljanoj sekvenci u ciljanoj DNK; i
In the first emulsion the number of oil droplets with a size >1.2 um may be 5×1011/ml or less, e.g. 
Postupak prema zahtjevu 1 ili zahtjevu 2, naznačen time da broj uljnih kapljica koje imaju veličinu od >1.2 um u prvoj emulziji je 5 x 10"!
A combination of GPR119 agonist and DPP-IV inhibitor in accordance with the present invention is useful in treating or preventing diabetes and conditions related thereto. 
Postupak u skladu sa zahtjevom 12 ili zahtjevom 13, naznačen time, da GPR119 agonist je agonist humanog GPR119.
The isolated antigen binding protein of item 6, wherein the isolated antigen binding protein has a Ki of less than 1 nM in a radiolabeled 125I-CGRP binding competition assay to membranes from cells expressing human CGRP R. The isolated antigen-binding protein of item 1, wherein the isolated antigen binding protein competes for binding to human CGRP R with a reference antibody, said reference antibody comprising (i) a heavy chain variable region comprising a sequence selected from the group consisting of SEQ ID NOs:161, 163, 164, 166 and 168; and (ii) a light chain variable region comprising a sequence selected from the group consisting of SEQ ID NOs: 140, 143, 146, 148 and 150. 
Monoklonsko protutijelo ili njegov antigen-vezujući fragment koji veže ljudski CGRP receptor, navedeni ljudski CGRP receptor obuhvaća ljudski CRLR polipeptid i ljudski RAMPI polipeptid, naznačeno time što se monoklonsko protutijelo ili njegov antigen-vezujući fragment veže za epitop formiran od aminokiselinskih ostataka iz oba polipeptida CRLR i RAMPI, te pri čemu se monoklonsko protutijelo ili njegov antigen-vezujući fragment natječe za vezanje na ljudski CGRP receptor s referentnim protutijelom, pri čemu navedeno referentno protutijelo sadrži (i) varijabilnu regiju teškog lanca koja sadrži sekvencu odabranu iz skupine koja se sastoji od SEQ ID NOs: 161, 163, 164, 166, 1 168; i (11) varijabilnu regiju laganog lanca koja sadrži sekvencu odabranu iz skupine koja se sastoji od SEQ ID NOs: 140, 143, 146, 148, i 150.
stirring the solution to obtain a suspension; 
(h) miješanje otopine da se dobije suspenzija;
The compound of claim 1, characterized by a differential scanning calorimetry trace substantially in accordance with that shown in FIG. 
Spoj sukladno patentnom zahtjevu 1, naznačen time, da mu trag diferencijalne pretražne kalorimetrije u biti u skladu s onim koji je prikazan na SI.
It will be appreciated that the preferred route will depend on the general condition and age of the subject to be treated, the nature of the condition to be treated and the active ingredient chosen. 
Treba uzeti u obzir da će preferirani način ovisiti o općem stanju i dobi osobe koja će biti liječena, prirodi stanja koje će se liječiti i odabranoj djelatnoj tvari.
and R2, the same or different, represent a hydrogen atom, or they are selected from linear or branched C1-C20 alkyl groups optionally halogenated, cycloalkyl groups optionally substituted; aryl groups optionally substituted; 
Ri i R,, isti ili različiti, predstavljaju atom vodika, ili su izabrani od linearnih ili granatih C;-C> alkil grupa koje su izborno halogenirane, cikloalkil grupa koje su izborno supstituirane; aril grupa koje su izborno supstituirane;
A pharmaceutical composition comprising a compound in accordance with any one of claims 1 to 17 and a therapeutically inert carrier. 
Farmaceutski sastav, naznačen time, da obuhvaća spoj prema bilo kojem od zahtjeva 1 do 17 i terapeutski inertan nosač.
% by weight of the inert nucleus; 
% težine inertne jezgre;
1, the second rotating shaft 7 is preferably moved by an electric motor 11 secured and integral to the rotating platform 6 . 
Poželjno je da se u prikazanom primjeru druga rotacijska osovina 7 pokreće pomoću elektromotora 11 koji je pričvršćen na rotirajuću platformu 6 i stoga sastavni dio navedene platforme.
The polypeptide of any preceding paragraph wherein the first proximal end does not disrupt a short repeat-long repeat-short repeat portion. 
Polipeptid u skladu s bilo kojim od prethodnih patentnih zahtjeva, naznačen time što prvi proksimalni kraj ne prekida dio s kratkim ponavljanjem-dugim ponavljanjem-kratkim ponavljanjem.
wherein, is hydroxy; and the other variable groups are as defined in claim 1, with an azide selected from diphenylphosphoryl azide (DPPA) or sodium azide (NaN3) to form a compound of said formula (II) wherein R5 is —N3 and the other variable groups are as defined in claim 1; and 
R5 je hidroksi; a druge promjenjive skupine su definirane kao u patentnom zahtjevu 1, s azidom kojeg se bira između difemlfosforil-azida (DPPA) ili natrijevog azida (NaN>), kako bi se dobilo spoj navedene formule (II), gdje je R5 -N;, a druge promjenjive skupine su definirane kao u patentnom zahtjevu 1; 1
The composition according to claim 1, wherein the carrageenan is a kappa-carrageenan. 
Sastav u skladu s patentnim zahtjevom 1, pri čemu je karagenan kappa-karagenan.
is hydrogen, alkyl, alkoxy, cycloalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, heterocyclyl or heterocyclylalkyl; is alkyl, alkenyl, aryl, cycloalkyl, heteroaryl or heterocyclyl, each of which may be optionally substituted with one or more R6's; 
je vodik, alkil, alkoksi, cikloalkil, aril, arilalkil, heteroaril, heteroarilalkil, heterociklil ili heterociklilalkil; je alkil, alkenil, aril, cikloalkil, heteroaril ili heterociklil, od kojih svaki može biti po izboru supstituiran jednim ili više R6;
In another preferred embodiment, the invention relates to the treatment of mammals, including humans, suffering from an eye disorder which is regarded as treatable or preventable through use of PDE 4 inhibitors. 
U slijedećem povoljnom obliku, izum se odnosi na liječenje sisavaca, uključujući i ljude, koji pate od očnih poremećaja za koje se smatra da se mogu liječiti ili spriječiti uporabom PDE 4 inhibitora.
The method of claim 1 or 2, characterized in that in step 1), a temperature of the exhaust gas from the electric power plant is between 110 and 140°C; a temperature of the exhaust gas after the first indirect heat exchange in the first heat exchanger is between 80 and 90°C; and a temperature of the heated air provided for the vegetable greenhouse and/or algae culturing house is between 40 and 50°C. 
Postupak prema zahtjevu 1 ili 2, naznačen time da je u koraku 1), temperatura ispušnog plina iz elektrane između 110 1 140*C; temperatura ispušnog plina nakon prve neizravne izmjene topline u prvom izmjenjivaču topline je između 80 i 90%C; i temperatura zagrijanog zraka predviđenog za staklenik povrća i/ili kuću za uzgoj algi je između 40 1 50*C.
A method according to claim 1, wherein the softening step comprises a method of heating selected from the group consisting of baking, frying, steaming, boiling, blanching or microwaving the vegetable. 
Metoda u skladu sa patentnim zahtjevom 1, gdje korak omekšavanja sadrži pečenje, prženje, kuhanje na pari, kuhanje, blanširanje ili kuhanje povrća u mikrovalnoj pećnici.
The compound of any one of claims 1-14, or a pharmaceutically acceptable salt thereof, wherein the alkylene in R2 is methylene. 
Spoj prema bilo kojem od patentnih zahtjeva od 1 do 14, naznačen time da se spoj ili njegova farmaceutski prihvatljiva sol u obliku čvrstog, polučvrstog ili tekućeg oblika davanja.
reacting the compound of formula I' with a compound of formula III to obtain a compound of formula IV' wherein X is as defined above, 
gdje je X isti kao što je gore definiran, (ili) redukcija nitro-skupine od spoja formule IV' kako bi se dobio spoj formule IV'"'
A plant according to claim 1, characterized in that the heating medium is seawater and the pressure through the heat exchanger (D) and NG/coolant heat exchanger (C) is maintained above the boiling pressure at seawater temperature. 
Postrojenje prema zahtjevu 1, naznačeno time što je medij za zagrijavanje morska voda, a tlak kroz izmjenjivač topline (D) i izmjenjivač topline prirodni plin/frashladno sredstvo (C) se održava iznad tlaka ključanja na temperaturi morske vode.